Horm Metab Res 2015; 47(09): 652-655
DOI: 10.1055/s-0035-1547234
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

Increased Risk of Unfavorable Metabolic Outcome in Patients with Clinically Nonfunctioning Pituitary Adenomas

B. A. Doğan
1  Endocrinology and Metabolism Disease, Darıca Farabi State Hospital, Kocaeli, Turkey
,
M. M. Tuna
2  Endocrinology and Metabolism Disease, Dicle University, Diyarbakır, Turkey
,
A. Arduç
3  Endocrine and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Diabetes, National Institutes of Health, Bethesda, Maryland, USA
,
M. N. Başaran
4  Endocrinology and Metabolism Disease, Ankara Numune Training and Research Hospital, Ankara, Turkey
,
K. Küçükler
5  Endocrinology and Metabolism Disease, Hitit University, Çorum, Turkey
,
I. Dağdelen
4  Endocrinology and Metabolism Disease, Ankara Numune Training and Research Hospital, Ankara, Turkey
,
D. Berker
4  Endocrinology and Metabolism Disease, Ankara Numune Training and Research Hospital, Ankara, Turkey
,
S. Güler
4  Endocrinology and Metabolism Disease, Ankara Numune Training and Research Hospital, Ankara, Turkey
5  Endocrinology and Metabolism Disease, Hitit University, Çorum, Turkey
› Author Affiliations
Further Information

Publication History

received 25 September 2014

accepted 03 February 2015

Publication Date:
06 March 2015 (eFirst)

Abstract

The aim of this study was to investigate atherosclerotic risk markers in women with clinically nonfunctioning pituitary adenomas (CNFAs). Records of 47 women with CNFAs and 73 healthy women who were treated as outpatients between January 2010 and March 2014 were evaluated retrospectively. All study data were obtained from file records. Lipid parameters, mean platelet volume (MPV), total testosterone (TT), androstenedione (AS), and dehydroepiandrostenedione sulfate (DHEAS) were recorded. Insulin resistance (IR) was calculated with homeostatic model assessment-insulin resistance (HOMA-IR). Among the atherosclerotic risk markers, the HOMA-IR and AS levels were higher in patients with CNFAs than in healthy subjects (p=0.003, p=0.021, respectively). A positive correlation between AS and insulin/HOMA-IR levels was found among the metabolic parameters in the patients with CNFAs (p=0.001, r=0.550, p=0.004, r=0.498, respectively). The data showed that patients with CNFAs had high atherosclerotic risk markers such as insulin resistance and hyperandrogenemia. Insulin resistance may also cause hyperandrogenemia in patients with CNFAs.